Document is current
Any future updates will be listed below
-
Authors
Derman, Benjamin A.
Cooperrider, Jennifer
Rosenblatt, Jacalyn
Avigan, David E.
Rampurwala, Murtuza
Barnidge, David
Major, Ajay https://orcid.org/0000-0001-7261-1335
Karrison, Theodore
Jiang, Ken
Ramsland, Aubrianna
Kubicki, Tadeusz https://orcid.org/0000-0001-7588-1453
Jakubowiak, Andrzej J. https://orcid.org/0000-0002-2597-6822
-
Funding
Funding for this research was provided by:
Amgen
Janssen Pharmaceuticals
Multiple Myeloma Research Foundation
- License Information
-
More Information
Article History
Received: 5 February 2024
Revised: 20 March 2024
Accepted: 25 March 2024
First Online: 29 May 2024
Competing interests
: BAD declares advisory board fees from Janssen and Cota, Inc. He serves as an independent reviewer for a clinical trial for BMS. Research funding from Amgen and GSK. JC has no disclosures. JR declares consulting/advisory board fees from Advare, Bioclinica, Bristol Myers Squibb, Karyopharm Therapeutics, Parexel, and Sanofi. DEA declares consulting/advisory board fees from Aviv Med Tech, Bristol Myers Squibb/Celgene, Chugai Pharma, Janseen, Juno Therapeutics, Karyopharm Therapeutics, Kowa Pharmaceutical, Legend Biotech, Partner Therapeutics, Sanofi, and Takeda; employment by Paraxel; research funding from Kite and Pharmacyclics. MR declares advisory board fees from AstraZeneca. DB is an employee of The Binding Site, part of Thermo Fisher, and may receive royalties from EXENT and LC–MS technology license from the Mayo Foundation. AM has no disclosures. Th.K. has no disclosures. KJ has no disclosures. TaK has no disclosures. AJJ declares honoraria and advisory board fees from Abbvie, Amgen, Bristol-Myers Squibb/Celgene, GlaxoSmithKline, Gracell, Janssen, and Sanofi.
